Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2022 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Revolution Medicines Third Quarter 2022 Earnings Webcast.
Source: insidermonkey.com
Stay updated with breaking news from Phase Ib Codebreak. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Good day and thank you for standing by. Welcome to the Revolution Medicines Third Quarter 2022 Earnings Webcast.
Results from two Amgen studies on Lumakras for lung cancer showed its ability to slow disease progression, although combining it with immunotherapy increased the risk for TRAEs.
Phase Ib CodeBreaK study evaluated Lumakras in over ten different investigational combination regimens - News - PharmaTimes